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from 132 SLE patients were analyzed. The infection was found
in 30 SLE patients. The mean disease activity score in infected
group was higher than the score in non-infected group.
(p < 0.001) Stress and non-compliance were signiﬁcant positively
associated with more disease activity (r = +0.242, r = +0.276,
p = 0.005, 0.001 respectively). Disease duration, SLE knowledge
and self-management were non-statistically signiﬁcant with
disease activity. Infection, stress and compliance were predicted
factors in disease activity model. CONCLUSIONS: Factors asso-
ciated with SLE disease activity were infection, stress and
non-compliance.
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OBJECTIVES: To contrast the factors that are associated with
metabolic syndrome risk for US adolescents overall and US His-
panic adolescents. METHODS: At risk is deﬁned as having three
or more of the following: elevated fasting glucose, elevated SBP,
elevated DBP, elevated triglycerides, elevated BMI, elevated waist
circumference, or low HDL. Logistic regression and NHANES
2003–2006 data were used to examine the impact on metabolic
syndrome risks; gender, race, ethnicity, immigrant status, income,
insurance, parental education, activity levels, number of school
lunches and breakfasts per week, milk consumption, language
preference, and number of meals outside the home per week. US
adolescents overall were compared with US Hispanic adoles-
cents. Weighted sample sizes for Hispanic adolescents and US
born adolescents were 8,178,714, and 50,837,204 respectively.
At risk is deﬁned as having three or more of the following:
elevated fasting glucose, elevated SBP, elevated DBP, elevated
triglycerides, elevated BMI, elevated waist circumference, or low
HDL. Logistic regression and NHANES 2003–2006 data were
used to examine the impact on metabolic syndrome risks; gender,
race, ethnicity, immigrant status, income, insurance, parental
education, activity levels, number of school lunches and break-
fasts per week, milk consumption, language preference, and
number of meals outside the home per week. US adolescents
overall were compared with US Hispanic adolescents. Weighted
sample sizes for Hispanic adolescents and US born adolescents
were 8,178,714, and 50,837,204 respectively. RESULTS: The
results of the regressions were vastly different between US ado-
lescents and US Hispanic (First Generation and Native) adoles-
cents. All variables in the models were statistically signiﬁcant.
Where US adolescent females faced a lower risk (42%) of having
metabolic syndrome, US Hispanic females faced a higher risk
(17%). Notably, for those Hispanics that were ﬁrst generation,
risk increased by 65%. For US adolescents overall, low or middle
income levels increased risk three times, while low and middle
income level US Hispanic adolescents had a risk decrease of 77%
and 69% respectively. For every meal eaten outside the home per
week (excluding school meals) metabolic syndrome risk increases
for US adolescents by 4% and by 13% for Hispanic US adoles-
cents. CONCLUSIONS: Adolescents with metabolic syndrome
are at risk for acute cardiovascular endpoints, higher medical
utilization and expenditure, and lower quality of life. Interven-
tions should focus on education regarding healthy eating outside
the home despite limited ﬁnancial resources. A surprising result
of this analysis is the high price of acculturation for Hispanic ﬁrst
generation adolescents.
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OBJECTIVES: To examine the 5-year economic consequences
of reimbursing laparoscopic adjustable gastric banding (LAGB)
in addition to laparoscopic gastric bypass (LGBY) for a large
US managed care organization. METHODS: We used a Markov
model to estimate surgical costs and outcomes, weight loss, and
obesity-related costs and outcomes for LAGB, LGBY and no
treatment over a 5-year period for a hypothetical 1-million-
member managed care plan. Weight loss was estimated from a
randomized clinical trial (LAGB causes somewhat less weight
loss than LGBY). Complication rates, treatment and adverse
event costs, and medical costs were estimated from published and
publicly-available sources (LAGB has less severe complications
than LGBY). The treatment-eligible population was estimated
from US obesity rates, treatment guidelines, and clinical experi-
ence. Market expansion and substitution between LAGB and
LGBY were projected from historical trends and physician/
patient surveys. Budgetary impact, measured in 2007 dollars,
was calculated as net cost with LAGB versus without LAGB;
deterministic sensitivity analyses identiﬁed model drivers.
RESULTS: Mean 5-year cost for LAGB was less than LGBY at
$41,800 versus $52,800 per surgically-treated patient, primarily
due to lower surgical and complication costs. The net budgetary
impact was 14.5 M over 5 years ($1.8 M in year 1, rising to
$3.6 M in year 5). Net 5-year costs associated with market
expansion totaled $47.9 M, while patients receiving LAGB
instead of LGBY saw net cost-savings totaling $33.4 M. Results
are sensitive to estimates of the proportion of patients that would
choose LGBY in the absence of the LAGB option (net budgetary
impact: +$32.8 M to -$5.2 M) and estimates of market expan-
sion (net budgetary impact: $12.3 M to $16.6 M). CONCLU-
SIONS: For a hypothetical 1-million-member managed-care
organization, the estimated 5-year budgetary impact of reimburs-
ing LAGB is approximately $14.5 M. Although plan expendi-
tures increase as additional patients seek surgical treatment,
substantial savings are realized for patients receiving LAGB
instead of LGBY.
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OBJECTIVES: This study aims to estimate the budget impact of
deferasirox (a once-daily oral iron chelator recently marketed in
Italy) in patients with beta-thalassaemia major and chronic iron
overload from blood transfusions, who live in the Veneto region.
Our analysis compares the costs of deferasirox versus deferox-
amine (which is the current standard of care for these patients)
and versus deferiprone, another oral iron chelator that is
licensed only for the treatment of iron-overloaded thalassaemic
patients, when deferoxamine is contraindicated or inadequate.
METHODS: Our analyses was conducted from the perspective
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of the Italian health care system. The following direct medical
care costs were considered: drug costs (cost to the hospital at the
dosage range reported in the SPC), administration costs (medical
devices for deferoxamine, hospital cost), laboratory assessments
(cost of laboratory exams from SPC, using hospital reimburse-
ment tariff). All costs are expressed as Euros (year 2007 values).
We considered the patients with beta thalassaemia major that
live in the Veneto region. RESULTS: According to the Regional
Rare Diseases Register, in Veneto 170 patients are affected
by thalassaemia. 153 are eligible for deferasirox treatment.
Switching all patients from deferoxamine (estimated annual
costs: €734,808–1,327,797), to deferasirox (estimated annual
costs: €3,615,382–5,575,618), would cause an expenditure
increase of €2,881,074–4,247,823/year. From drug utilization
data, it is estimated that about 15 patients with beta-talassemia
are treated with deferiprone. In this scenario, the budget impact
of switching all patients to deferasirox would be €2,858,547–
4,283,481. CONCLUSIONS: Besides the advantage of the oral
administration instead of continous subcutaneous infusion by
pump, the impact of deferasirox on the regional budget is rel-
evant. Alternative scenarios may take into account switching to
the new drug only patients subgroups (e.g., patients who do not
respond to deferoxamine) or patients for whom quality of life is
strongly affected by the infusion pump.
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OBJECTIVES: The budget impact of introducing OROS® hydro-
morphone once-daily, a novel therapy for treating patients with
severe chronic cancer and non-cancer pain, was determined in
the German health care system. METHODS: The perspective of
the social health insurance over a one-year time horizon was
adopted. An Excel® based hypothetical budget impact model
calculating the cost consequences of using strong opioids (WHO
step III) was developed. The model accounts for the costs of
opioids, breakthrough pain and adverse events. Patient numbers
are calculated using epidemiological data from the literature;
adverse event rates are based on literature. Comparators
included sustained-release (SR) morphine (twice-daily),
controlled-release (CR) oxycodone (twice-daily), hydromor-
phone (twice-daily), transdermal fentanyl and transdermal
buprenorphine. Initial prescription share of OROS® hydromor-
phone was 2.4% (October 2007 MAT). This share was hypo-
thetically extended to 8%. It was assumed that this increase in
prescription of OROS® hydromorphone is gained by switching
patients from their previous medication to OROS® hydromor-
phone (proportionally to the prescription share of the compara-
tor at start). Titration and maintenance dosing schemes taken
from previous analyses are used to model the switch. Morphine
equivalence of hydromorphone was chosen according to SmPC.
RESULTS: The number of patients treated was estimated to be
882,347 per year. The model predicted that the introduction of
OROS® HM would lower the per patient drug cost from €684.28
to €679.52 (2008 public prices). The model also predicts that
as the use of OROS® HM increases, the total budget for
strong opioids decreases. If the prescription share of OROS® HM
increased to 8% the total budget for strong opioids would
decrease by €4,199,327. CONCLUSIONS: Our analysis suggests
that under current circumstances the use of OROS® hydromor-
phone to treat patients with severe chronic pain will reduce the
overall budget spent on strong opioids.
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OBJECTIVES: Study costs of carrying out a genetic screening
programme per 100.000 individuals from the Spanish population
under 30 years of age for Hereditary Hemochromatosis (HH),
based on the calculated penetrance of HH in the South-West
Healthcare Area 11 of Madrid, and the published prevalence of
the HH genotype in Spain. METHODS: Retrospective cross-
sectional study of HFE genotyping requests from a subpopula-
tion in South West Madrid pre-screened for high ferritin values,
between January 2000 and June 2006. Based on our population’s
genotype and phenotype, clinical penetrance was calculated in a
previous study. Costs, extracted from a Spanish Medical Cost
database (SOYKOS), involved in treatment of HH-associated
diseases, biochemical testing, genetic testing, treatment of phe-
notypical HH patients and follow up were analysed to compare
the costs for genetic screening versus no screening. RESULTS:
From our data, for the main HH-associated diseases, we have
previously calculated a clinical penetrance, for HH genotype, in
the population studied, of 1.11%, compared to 0.08% for those
with wild-type HFE genotype. The main HH-associated patholo-
gies considered are hepatopathy, diabetes and arthropathy. Cost
for genetic testing of 100,000 Spanish individuals under 30 years
of, biochemical follow up of those with HH genotype, and treat-
ment of those with HH genotype and phenotype amounts to
€1,808,353.29, equivalent to €1433.49/case with HH geno-
type detected and €129,168.09 per phenotypical case with HH
genotype detected. Treatment of HH-associated pathologies,
if no other preventive intervention is undertaken (biochemical
monitoring, preventive phlebotomy treatment), would cost
€407,043.70. CONCLUSIONS: The extremely low penetrance
of HH-associated pathologies related to the HH genotype, sug-
gests that a genetic screening programme for the population
proposed is not economically justiﬁed for the Spanish National
Healthcare System. However, this does not exclude genetic
screening of ﬁrst degree relatives of HH patients and their
subsequent biochemical follow-up which could prove to be
appropriate.
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OBJECTIVES: NICE has recommended etanercept for use in
patients with severe chronic plaque psoriasis, deﬁned as a Pso-
riasis Area and Severity Index (PASI) of 10 or more and a
Dermatology Life Quality Index (DLQI) of more than 10. This
study assessed the cost-effectiveness of intermittent therapy with
etanercept 25 mg twice weekly (biw) or 50 mg biw compared
with no systemic therapy (NST) in patients with less severe
disease. METHODS: An economic model was constructed to
estimate the incremental cost per quality adjusted life year
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